NU-WARFARIN 2.5 MG
WARFARIN SODIUM : 2.5 MG · DIN 02335646 · NU-PHARM INC
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is NU-WARFARIN?
NU-WARFARIN 2.5 MG contains WARFARIN SODIUM : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02335646, held by NU-PHARM INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 28-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NU-WARFARIN used for?
Prophylaxis/treatment of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization; adjunct in prophylaxis of systemic embolism after MI (stroke, reinfarction, death).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02335646 |
|---|---|
| Brand name | NU-WARFARIN |
| Generic / active ingredient | WARFARIN SODIUM : 2.5 MG |
| Manufacturer | NU-PHARM INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AA03 WARFARIN |
| AHFS class | 20:12.04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 28-Mar-2018 |
How is it administered?
Individualized dosage based on PT ratio/INR. Heparin may be used concomitantly during initiation. Narrow therapeutic range requires frequent monitoring.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text.
How is it supplied?
Not explicitly stated in provided text (standard strengths 1, 2, 2.5, 3, 4, 5, 10 mg).
Contraindications
Pregnancy; haemorrhagic tendencies; recent/contemplated surgery of CNS or eye; active ulceration/bleeding of GI, GU, or respiratory tracts; aneurysms; bacterial endocarditis; malignant hypertension.
Warnings and precautions
Major or fatal bleeding risk. INR monitoring essential. Risk of necrosis/gangrene. Purple toe syndrome. Enhanced release of atheromatous plaque emboli.
What can be used instead?
Other Canadian products sharing ATC code B01AA03 WARFARIN. 16 of 60 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-WARFARIN | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02242924 |
| APO-WARFARIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02242929 |
| APO-WARFARIN | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02242925 |
| APO-WARFARIN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242926 |
| APO-WARFARIN | 3 MG | TABLET | APOTEX INC | MARKETED | DIN 02245618 |
| APO-WARFARIN | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02242927 |
| APO-WARFARIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242928 |
| TARO-WARFARIN | 1 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242680 |
| TARO-WARFARIN | 10 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242687 |
| TARO-WARFARIN | 2 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242681 |
Who else supplies WARFARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. WARFARIN appears in 2044 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.